Physician profile
Danielle L Roberts
NPI 1568632081
$4,906.45
in general payments reported to CMS, 2019-2025
15 companies · $807 in 2025
The $807 reported for 2025 was more than what 76% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,605 · 2022: $344 · 2023: $1,313 · 2024: $837 · 2025: $807.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,484 · Consulting Fee: $1,320 · Education: $153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,484.32 |
| Consulting Fee | $1,320.00 |
| Education | $152.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $1,247.99 | 2021-2025 | |
| Kadmon Pharmaceuticals LLC | $678.00 | 2021 | |
| Teleflex LLC | $662.99 | 2021-2022 | |
| Pfizer INC. | $570.42 | 2023-2024 | |
| Janssen Scientific Affairs, LLC | $543.15 | 2024-2025 | Darzalex, Talvey, Tecvayli |
| Abbvie INC. | $243.11 | 2023-2025 | |
| Janssen Biotech, INC. | $184.71 | 2024-2025 | Tecvayli, Darzalex, Talvey |
| Sanofi-Aventis U.S. LLC | $153.79 | 2024-2025 | |
| Agios Pharmaceuticals, INC. | $124.96 | 2025 | Pyrukynd |
| E.R. Squibb & Sons, L.L.C. | $122.46 | 2024 | |
| Kite Pharma, INC. | $119.88 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $108.80 | 2022 | |
| Karyopharm Therapeutics INC. | $90.21 | 2024 | Xpovio |
| Celgene Corporation | $41.50 | 2025 | Abecma |
| Bausch Health US, LLC | $14.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Roberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.